1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

DSKYF
Daiichi Sankyo Company, LimitedUS flagOther OTC
16.40
USD
-0.65
- -
29.84BMarket Cap
Daiichi Sankyo Company, Limited
DSKYF
(Other OTC)

Recent

price

16.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
458.08
444.5
471
425.75
435.32
477.02
474.18
484.83
478.41
505.08
496.31
545.18
666.9
835.35
994.67
- -
- -
Revenue per Share
33.2
4.92
30.32
28.86
152.52
39.79
26.54
30.44
48.07
66.4
39.17
34.94
56.96
104.69
155.96
- -
- -
Basic EPS, GAAP
49.72
13.67
23.65
-1.79
22.8
47.32
41.34
35.56
13.08
74.1
66.06
32.63
24.59
248.5
-70.68
- -
- -
Free Cash Flow per Basic Share
20.01
20
20
20
20.01
23.44
21.79
23.44
23.33
23.33
25.24
26.99
28.49
34.99
60.28
- -
- -
Dividend per Share
390.32
383.97
395.89
413.18
544.15
555.55
578.55
593.8
667.63
713.14
733.15
636.65
668.63
751.44
794.7
- -
- -
Book Value per Share
346.05
281.44
323.24
355.42
490.66
456.7
434.87
446.37
515.8
543.78
526.74
575.72
619.66
736.32
674.53
- -
- -
Tangible Book Value per Share
2,112
2,112
2,112
2,112
2,112
2,068
2,014
1,980
1,943
1,944
1,939
1,917
1,917
1,917
1,896
1,850
1,854
Basic Weighted Avg Shares
967,365
938,677
994,659
899,126
919,372
986,446
955,124
960,195
929,717
981,793
962,516
1,044,892
1,278,478
1,601,688
1,886,256
- -
- -
Sales/Revenue/Turnover
27.97
6.39
9.93
12.56
8.09
13.22
9.31
7.94
9
14.14
6.63
6.99
9.43
13.21
17.6
- -
- -
Operating Margin (%)
55,214
57,381
45,260
38,364
42,023
44,306
47,373
46,680
46,169
52,611
57,382
58,245
67,789
59,646
68,649
- -
- -
Depreciation Expense
70,121
10,383
64,027
60,943
322,119
82,282
53,466
60,282
93,409
129,074
75,958
66,972
109,188
200,731
295,756
- -
- -
Net Income, GAAP
34.72
117.23
31.25
41.75
45.5
34.31
45.92
26.18
- -
8.64
- -
8.9
13.93
15.27
16.84
- -
- -
Effective Tax Rate (%)
7.25
1.11
6.44
6.78
35.04
8.34
5.6
6.28
10.05
13.15
7.89
6.41
8.54
12.53
15.68
- -
- -
Profit Margin (%)
587,123
371,717
405,230
529,415
487,838
745,574
870,971
848,440
1,008,640
1,033,048
914,849
950,003
964,788
1,450,625
1,155,401
- -
- -
Working Capital
224,036
193,926
200,742
263,289
201,000
181,000
280,543
260,564
220,585
183,811
163,441
143,067
101,692
101,314
100,933
- -
- -
LT Debt
887,702
851,308
938,480
1,007,527
1,307,041
1,233,521
1,171,428
1,133,041
1,249,705
1,306,274
1,272,053
1,350,872
1,445,854
1,688,603
1,623,416
- -
- -
Total Equity
14.81
-0.89
5.75
4.94
2.73
5.66
3.21
3.77
- -
8.28
- -
4.46
6.63
10.4
15.24
- -
- -
Return on Invested Capital (%)
5.73
2.29
6.59
5.79
24.25
6.8
4.55
4.41
- -
8.6
- -
4.83
8.3
13.85
19.4
- -
- -
Return on Capital (%)
8.65
1.27
7.78
7.13
31.86
7.16
4.62
5.15
7.55
9.62
5.41
5.07
8.73
14.75
20.07
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'26
ST Debt
- -
400
- -
LT Borrowings
- -
101,123
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
1,896
- -
Market Capitalization
10,523,111
8,732,830
6,247,740

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'26
Total Current Assets
- -
1,896,221
- -
Cash, Cash Equivalents & STI
- -
848,469
- -
Accounts Receivable, Net
- -
531,836
- -
Inventories
- -
453,088
- -
Total Current Liabilities
- -
643,931
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
400
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
350,835
375,508
446,925
428,419
1,601,688
2025
- -
- -
- -
- -
1,886,256
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
29.74
20.86
34.71
- -
104.69
2025
- -
- -
- -
- -
155.96
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15.02
-0.02
20.02
- -
34.99
2025
- -
- -
- -
- -
60.28
2026
- -
- -
- -
- -
- -
Similar Companies
BCWORLD PHARM. Co., Ltd. (200780.KQ)
Johnson & Johnson (JNJ)
Vectura Group plc (VEC.L)
Grifols, S.A. (GRF.MC)
Mayne Pharma Group Limited (MYX.AX)
Astellas Pharma Inc. (4503.T)
Business
Daiichi Sankyo Company, Limited is a global pharmaceutical company headquartered in Tokyo, Japan, founded in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company. It operates primarily in the pharmaceutical industry with a strong focus on oncology, cardiovascular, and rare diseases. Its core products include oncology therapies such as Enhertu (an antibody-drug conjugate for breast cancer and other cancers), Datopotamab Deruxtecan (Datroway) targeting solid tumors, cardiovascular drugs, and a portfolio of small molecule and biologic medicines. Daiichi Sankyo develops and markets prescription pharmaceuticals, vaccines, and drug discovery platforms, including proprietary DXd technology for antibody-drug conjugates. In recent years, Daiichi Sankyo has made strategic advances with significant partnerships and acquisitions to strengthen its oncology pipeline and global presence. Notably, it expanded its pipeline through the acquisition of solid tumor ADC assets from Glycotope for $132.5 million and entered a $22 billion strategic alliance with Merck to develop ADC therapies targeting multiple cancer antigens. The company also launched new vaccine offerings in Japan including DAICHIRONA mRNA COVID-19 vaccine and an influenza vaccine FluMist. In 2025, Daiichi Sankyo initiated several clinical trials including the IDeate-Prostate02 trial for metastatic castration-resistant prostate cancer and DESTINY-Lung06 phase 3 trial for HER2 overexpressing non-small cell lung cancer. It established Daiichi Sankyo Vietnam to broaden its operational footprint in Asia. Daiichi Sankyo continues to focus on digital transformation and agile management to enhance innovation and operational efficiency. The company operates globally with significant markets in Japan, the United States, Europe, and Asia. Its portfolio includes cardiovascular products, oncology drugs, vaccines, and rare disease treatments, serving healthcare providers, hospitals, and patients worldwide. Daiichi Sankyo holds a competitive position as the second-largest pharmaceutical company in Japan and emphasizes oncology as a strategic growth pillar under its 2025 Vision to become a global pharma innovator. Overall, Daiichi Sankyo combines a comprehensive range of pharmaceutical products with an evolving pipeline driven by advanced antibody-drug conjugate technologies, recent strategic partnerships with industry leaders, and expansion in emerging markets. Its headquarters remain in Tokyo, Japan, with a broad global operational network supporting its innovation-driven healthcare mission.

Company News

APIChat

  • seekingalpha.com

    Daiichi Sankyo Company, Limited (DSNKY) Q4 2026 Earnings Call Transcript

  • seekingalpha.com

    Daiichi Sankyo Company, Limited (DSKYF) Q1 FY2025 Earnings Call Transcript

  • seekingalpha.com

    Daiichi Sankyo Company, Limited (DSKYF) FY2024 Earnings Call Transcript

  • seekingalpha.com

    Daiichi Sankyo Company, Limited (DSKYF) Q3 2024 Earnings Call Transcript

  • seekingalpha.com

    Daiichi Sankyo Company, Limited (DSKYF) Q1 2024 Earnings Call Transcript